Interestingly, afatinib (AFA) is a second-generation tyrosine kinase inhibitor (TKI) with high selectivity in inhibiting the ErbB family through covalent and irreversible binding to epidermal growth factor receptors (EGFR), making afatinib a potent treatment [12], which could stand by itself as a safe and effective first- and second-line monotherapy for survival improvement of NSCLC patients [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.